KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment

Documenti analoghi

• Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer (“KEYNOTE 045”)
  di: Fishman, Mayer
  Pubblicazione: (2019)
• A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)()()()
  di: Si, Lu, et al.
  Pubblicazione: (2019)
• Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
  di: Isaacs, James, et al.
  Pubblicazione: (2020)
• Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
  di: Gadgeel, Shirish M., et al.
  Pubblicazione: (2018)
• KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
  di: Cummings, Amy Lauren, et al.
  Pubblicazione: (2019)